Real-world lecanemab data show ARIA risks and limited cognitive evidence
A meta-analysis of 37 real-world lecanemab studies found ARIA in 15.1% of cases, with higher rates among APOE ε4 homozygotes ...
A meta-analysis of 37 real-world lecanemab studies found ARIA in 15.1% of cases, with higher rates among APOE ε4 homozygotes ...
A new qualitative study from West China Hospital reveals how family caregivers of Alzheimer's patients in China experience lecanemab treatment, ...
A combined real-world cohort and FAERS analysis finds lecanemab generally safe in Alzheimer's patients but flags a strong, unlabeled signal ...
A Sutter Health virtual review board allowed general neurologists to safely prescribe and monitor amyloid-targeting Alzheimer's therapies in community settings, ...
A new Journal of Neurology Comment argues the Alzheimer's field has avoided honestly assessing whether licensed anti-amyloid drugs deliver clinically ...
New research reveals that amyloid deposition in the cerebellar cortex systematically distorts standard amyloid PET quantification in Alzheimer's disease, prompting ...
A USC-developed blood-based screening algorithm cut the rate of unnecessary PET scans among Alzheimer's clinical trial candidates from over 70 ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine